GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InNexus Biotechnology Inc (GREY:IXSBF) » Definitions » Total Current Liabilities

InNexus Biotechnology (InNexus Biotechnology) Total Current Liabilities : $9.54 Mil (As of Mar. 2011)


View and export this data going back to . Start your Free Trial

What is InNexus Biotechnology Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. InNexus Biotechnology's total current liabilities for the quarter that ended in Mar. 2011 was $9.54


InNexus Biotechnology Total Current Liabilities Historical Data

The historical data trend for InNexus Biotechnology's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InNexus Biotechnology Total Current Liabilities Chart

InNexus Biotechnology Annual Data
Trend Jun01 Jun02 Jun03 Jun04 Jun05 Jun06 Jun07 Jun08 Jun09 Jun10
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.21 0.86 1.52 3.58 8.26

InNexus Biotechnology Quarterly Data
Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.96 8.26 8.27 8.86 9.54

InNexus Biotechnology Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

InNexus Biotechnology's Total Current Liabilities for the fiscal year that ended in Jun. 2010 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=5.013+3.242
+Other Current Liabilities+Current Deferred Liabilities
=1.7763568394003E-15+0
=8.26

InNexus Biotechnology's Total Current Liabilities for the quarter that ended in Mar. 2011 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=2.934+6.609
+Other Current Liabilities+Current Deferred Liabilities
=-0.0019999999999989+0
=9.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.


Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term


InNexus Biotechnology Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of InNexus Biotechnology's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


InNexus Biotechnology (InNexus Biotechnology) Business Description

Traded in Other Exchanges
N/A
Address
1055 West Georgia Street, 1500 Royal Centre, Vancouver, BC, CAN, V6E 4N7
InNexus Biotechnology Inc is engaged in commercializing the next generation of monoclonal antibodies based on its DXL technology, which improves the potency of existing antibody products while opening new markets and disease applications.

InNexus Biotechnology (InNexus Biotechnology) Headlines

No Headlines